A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2023-02-07
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-04-02 (study day 45); relationship: N
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-11 (study day 145); relationship: not assessed
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-03-12 (study day 390); relationship: N
Data queries
No data queries.